I sure hope Bristol-Myers is right. At $735 million net of cash, ZymoGenetics doesn't come cheap with Bristol-Myers blowing through about 10% of the $7.5 billion it had in the bank at the end of the second quarter.
Technically, ZymoGenetics has a drug on the market, but it only sold $20.9 million worth of Recothrom in the first half of the year. The drug that helps stop bleeding during surgery has to compete against King Pharmaceuticals'
But Bristol-Myers is basically buying ZymoGenetics for its pipeline. The companies are partners on pegylated-interferon lambda, a treatment for hepatitis C. The hope is that the drug produces fewer side effects and can unseat Roche's Pegasys and Merck's
Who knows, maybe I'm overreacting here. Bristol-Myers seems to have made a good move acquiring partner Medarex to gain full control of their melanoma drug ipilimumab. And management was willing to walk away from ImClone Systems rather than get into a bidding war with Eli Lilly
48% returns in a bear market? Alex Dumortier has the answer.
Johnson & Johnson is a Motley Fool Income Investor recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.